Literature DB >> 28011856

Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia.

A Fountas1, S Tigas2, A Tsatsoulis2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28011856     DOI: 10.1093/qjmed/hcw206

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


× No keyword cloud information.
  2 in total

Review 1.  Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment.

Authors:  Themistoklis Tzotzas; Apostolos Goropoulos; Spyridon Karras; Alexandra Terzaki; Athanasios Siolos; Argyrios Doumas; Thomas Zaramboukas; Stelios Tigas
Journal:  Hormones (Athens)       Date:  2022-01-07       Impact factor: 2.885

2.  Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia.

Authors:  Yulong Li; Chris Y Fan; Andrea Manni; William F Simonds
Journal:  BMJ Case Rep       Date:  2020-04-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.